Genus (LON:GNS) Releases Quarterly Earnings Results

Genus (LON:GNS) released its quarterly earnings data on Thursday. The company reported GBX 110.30 EPS for the quarter, Digital Look Earnings reports. Genus had a net margin of 7.07% and a return on equity of 9.70%.

Here are the key takeaways from Genus’ conference call:

• FY 2026 results were strong: adjusted profit before tax and adjusted EPS each rose 35%, while free cash flow increased to £62 million and leverage fell to 0.4x.
• Genus announced a £60 million share buyback for FY 2027 and recommended a 10% increase in the full-year dividend to 35.2 pence per share, reflecting confidence in cash generation and future growth.
• PIC delivered broad-based growth, including 52% royalty-revenue growth in China and market-share gains, while the new China joint venture is expected to support further expansion in the world’s largest porcine market.
• PRP regulatory progress continued with approvals or favorable determinations in Argentina, Canada, Uruguay, and Peru; commercialization is now beginning in selected Latin American markets, although approvals in Mexico and China remain pending.
• Management expects FY 2027 underlying adjusted profit before tax to be only moderately higher, with growth weighted toward the second half due to weak agricultural markets, North American disease pressures, lower Brazilian growth, depressed dairy conditions, and higher PRP and product-development costs.

Genus Stock Performance

Shares of LON:GNS traded down GBX 74 on Thursday, reaching GBX 2,160. 543,824 shares of the company’s stock were exchanged, compared to its average volume of 769,729. The company has a fifty day moving average of GBX 2,223.11 and a 200-day moving average of GBX 2,382.24. Genus has a twelve month low of GBX 1,943 and a twelve month high of GBX 3,220. The company has a market capitalization of £1.43 billion, a price-to-earnings ratio of 30.42, a PEG ratio of 2.87 and a beta of 0.90. The company has a current ratio of 2.25, a quick ratio of 1.08 and a debt-to-equity ratio of 51.73.

Insider Buying and Selling at Genus

In related news, insider Celia Baxter purchased 2,336 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The stock was acquired at an average cost of GBX 2,140 per share, for a total transaction of £49,990.40. Insiders own 0.71% of the company’s stock.

Analyst Ratings Changes

Separately, Berenberg Bank reaffirmed a “buy” rating and issued a GBX 3,350 target price on shares of Genus in a research report on Thursday. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, Genus has an average rating of “Buy” and a consensus target price of GBX 3,216.67.

Genus News Summary

Here are the key news stories impacting Genus this week:

• Positive Sentiment: £60 million share buyback: Genus launched a repurchase programme, signalling management’s confidence in the company’s growth prospects and potentially supporting earnings per share by reducing the share count. Genus Launches £60 Mln Share Buyback Programme
• Positive Sentiment: Profit growth and lower leverage: FY26 pretax profit increased, while the company reduced leverage following developments involving its China joint venture. These factors strengthen the balance sheet and provide capacity for shareholder returns. Genus boosts profits, cuts leverage and launches £60m buyback after China JV
• Positive Sentiment: Analyst support: Berenberg reaffirmed its “buy” rating and set a GBX 3,350 price target, implying substantial upside from the current trading level. Investors Chronicle also described the recent weakness as a potential buying opportunity. Genus share price weakness offers buying opportunity
• Neutral Sentiment: Genus reported quarterly EPS of GBX 110.30, with a 7.07% net margin and 9.70% return on equity. The results indicate profitability, but investors focused more heavily on forward guidance and revenue performance. Genus earnings results
• Negative Sentiment: Moderating FY27 growth and revenue miss: Genus forecast only moderate operating-profit growth for FY27 and missed revenue expectations. The cautious outlook raises concerns about near-term demand and earnings momentum, prompting the sell-off despite the improved FY26 profit result. Genus Shares Fall 7% as Company Forecasts Moderate FY27 Operating Profit Growth

Genus Company Profile

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.